The multistep process of TP53 mutation expansion during myeloproliferative neoplasm
(MPN) transformation into acute myeloid leukemia (AML) has been documented …

Patients with myeloproliferative neoplasms (MPNs) are at significant, cumulative risk of
leukemic transformation to acute myeloid leukemia (AML), which is associated with adverse …

Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of
myeloid cells and the risk of transformation into myelofibrosis or acute myeloid leukemia …

Chronic myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET) and
primary myelofibrosis (PMF), result from interactions between initiating growth factor …

Abstract Abstract 3840 Background: Patients with myeloproliferative neoplasms (MPN)
harbor a multitude of somatic mutations involving JAK2, MPL, LNK, CBL, TET2, ASXL1 …

Although somatic mutations influence the pathogenesis, phenotype, and outcome of
myeloproliferative neoplasms (MPNs), little is known about their impact on molecular …

There is a paucity of data regarding the impact of mutations on outcomes in accelerated-
phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is …

In recent years, a series of studies have provided genetic insight into the pathogenesis of
myeloproliferative neoplasms (MPNs). It is now known that JAK2V617F mutations are …

Since the discovery of JAK2 V617F as a highly prevalent somatic acquired mutation in the
majority of myeloproliferative neoplasms (MPNs), it has become clear that these diseases …

Abstract Background JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is
found in the majority of patients with Ph-myeloproliferative neoplasms (MPNs), a group of …